Re: TD Zenith Capital Corp | Grey Market : ZHCLF
in response to
by
...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Message: Re: TD Zenith Capital Corp | Grey Market : ZHCLF
Yahoo's (ZHCLF) Company Profile:
Zenith Capital Corp. (ZHCLF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5300+0.4591 (+647.53%)
At close: October 19 3:19PM EDT
"Company Profile
815 - 8th Avenue SW
Suite 600
Calgary, AB T2P 3P2
Canada
http://www.zenithepigenetics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Zenith Capital Corp., a biotechnology investment company, develops bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. Its lead compound ZEN-3694 which is in phase II clinical trials for the treatment of metastatic castration resistant prostate cancer and in a phase 1b/2 clinical trial for triple negative breast cancer. The company was incorporated in 2013 and is based in Calgary, Canada."
Koo
1 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply